HTA128 Reassessment of Orphan Drugs After Exceeding the 50 Mio. Euro Revenue Threshold: Effects on Added Benefit and Price Discount

Autor:	RO Michel, JF Löpmeier, A Ingendoh-Tsakmakidis, N Italia, W Kulp
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S321
ISSN:	1098-3015
DOI:	10.1016/j.jval.2022.09.1586
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1977c995a69d140c4df52fa4920220b8 https://doi.org/10.1016/j.jval.2022.09.1586 Zobrazit plný text záznamu Full Text from ScienceDirect